Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression

Psychoneuroendocrinology

Volumn 22, Issue 7, 1997, Pages 539-548

  Abel, Kathryn M ^a,c   O'Keane, Veronica ^b   Murray, Robin M ^a   Cleare, Anthony J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Cortisol; D fenfluramine; Defect symptoms; Negative symptoms; Neuroendocrine; Prolactin; Serotonin

Indexed keywords

DEXFENFLURAMINE; HYDROCORTISONE; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ADULT; ANXIETY; DEPRESSIVE DISORDER; FEMALE; FENFLURAMINE; HUMANS; HYDROCORTISONE; MALE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0030693979     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(97)00050-4     Document Type: Article

References (42)

1. Abel, K. M., O'Keane, V. and Murray, R. M. (1996) Enhancement of the prolactin response to D-fenfluramine in drug-naive schizophrenic patients. British Journal of Psychiatry 168, 57-61.
2. Altomonte, L., Zoli, A., Alesi, F., Ghirlandi, G., Manna, R. and Greco, A. (1990) Effects of fenfluramine on GH and PRL secretion in obese subjects. Hormone Research 27, 190-194.
3. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. American Psychiatric Association, Washington DC.
4. Bleich, A., Brown, S. L., Kahn, R. and van Praag, H. M. (1988) The role of serotonin in schizophrenia. Schizophrenia Bulletin 14(2), 297-315.
5. Blier, P., de Montigny, C. and Chaput, Y. (1990) A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. Journal of Clinical Psychiatry 51(4 suppl.), 14-20.
6. Carpenter, W. T. (1995) Serotonin-dopamine antagonists and treatment of negative symptoms. Journal of Clinical Psychopharmacology 15(suppl.1), 30S-35S.
7. Ceulemans, D. L., Gelders, Y. G., Hoppenbrouwers, M. L., Reyntjens, A. J. and Janssen, P. A. (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology-Berlin 85(3), 329-332.
8. Cleare, A. J., Murray, R. M. and O'Keane, V. (1996) Reduced prolactin and cortisol responses to D-fenfluramine in major depression. Neuropsychopharmacology 14, 349-354.
9. Cowen, P. J., Gadhvi, H., Gosden, B. and Kolakowska, T. (1985) Responses of prolactin and growth hormone to L-tryptophan infusion: effects in normal subjects and schizophrenic patients receiving neuroleptics. Psychopharmacology-Berlin 86(1-2), 164-169.
10. Csernansky, J. G., Wrona, C. T., Bardgett, M. E., Early, T. S. and Newcomer, J. W. (1993) Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics. Psychopharmacology 110, 145-151.
11. Duinkerke, S. J., Botter, P. A., Jansen, A. A., van Dongen, P. A., van Haaften, A. J., Boom, A. J., van-Laarhoven, J. H. and Busard, H. L. (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. British Journal of Psychiatry 163, 451-455.
12. Duval, F., Cambon, N., Mokrani, M. C., Crocq, M. A., Bailey, P., Diep, T. S., Andrade, E. E. and Macher, J. P. (1994) Endocrine responses to D,L-and D-fenfluramine in psychiatry. Biological Psychiatry 35, 646.
13. Garattini, S., Mennini, T. and Samanin, R. (1987) From fenfluramine racemate to D-fenfluramine. Annals of the New York Academy of Science 499, 156-166.
14. Goodall, E. M., Cowen, P. J., Franklin, M. and Silverstone, T. (1993) Ritanserin attenuates anorectic, endocrine and thermic responses to D-fenfluramine in human volunteers. Psychopharmacology 112, 461-466.
15. Hamilton, M. (1960) A rating scale for depression. Journal of Neurology and Neurosurgery in Psychiatry 23, 56-62.
16. Hedlund, J. L. and Vieweg, B. W. (1980) The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. Journal of Operational Psychiatry 11, 48-64.
17. Hillert, A., Maier, W., Wetzel, H. and Benkert, O. (1992) Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome. A functional approach. Pharmacopsychiatry 25, 213-217.
18. Hogarty, G. E., McEvoy, J. P., Ulrich, R. F., DiBarry, A. L., Bartone, P., Cooley, S., Hammill, K., Carter, M., Munetz, M. R. and Perel, J. (1995) Pharmacology of impaired affect in recovering schizophrenic patients. Archives of General Psychiatry 52, 29-41.
19. Hoshino, Y., Kaneko, M., Kumashiro, H. and Tachibana, R. (1985) Endocrinological function in schizophrenic patients under haloperidol treatment: plasma PRL, HGH and 5HT levels after L-5HTP loading. Folia Psychiatry and Neurology of Japan 39, 25-31.
20. I nvernizzi, R., Berettera, C., Garratini, S. and Samanin, R. (1986) D-and L-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. European Journal of Pharmacology 120, 9-15.
21. Iqbal, N., Asnis, G. M., Wetzler, S., Kahn, R. S., Kay, S. R. and van Praag, H. M. (1991) The MCPP challenge test in schizophrenia: hormonal and behavioral responses. Biological Psychiatry 30, 770-778.
22. Kolakowska, T., Cowen, P. J. and Murdock, P. (1987) Endocrine responses to tryptophan infusion in schizophrenic patients treated with neuroleptics. Psychoneuroendocrinology 12(3), 193-202.
23. Knight, R. A. and Roff, J. D. (1985) Affectivity in schizophrenia. In Controversies in Schizophrenia, ed. M. Alpert. Guildford Press, New York.
24. Krystal, J. H., Seibyl, J. P., Price, L. H., Woods, S. W., Heninger, G. R., Aghajanian, G. K. and Charney, D. S. (1993) m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Archives of General Psychiatry 50, 624-635.
25. Lerer, B., Ran, A., Blacker, M., Silver, H., Weller, M. P., Drummer, D., Ebstein, B. and Calev, A. (1988) Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction. Schizophrenia Research 1, 405-410.
26. 1A receptor activation: effect of 5-HT receptor and beta-adrenoceptor antagonists. Journal of Clinical Endocrinology and Metabolism 70, 670-674.
27. Maes, M. and Meltzer, H. Y. (1995) The serotonin hypothesis of major depression. In Psychopharmacology, the Fourth Generation of Progress, eds F. Bloom and D. Kupfer. Raven Press, New York.
28. McBride, A., Ierney, H., DeMeo, M., Chen, J. S. and Mann, J. J. (1990) Effects of age and gender on serotonergic responsivity in normal adults. Biological Psychiatry 27, 1143-1155.
29. Meltzer, H. Y. (1992) Treatment of the neuroleptic non-responsive schizophrenic patient. Schizophrenia Bulletin 18, 515-542.
30. Meltzer, H. Y. and Maes, M. (1994) Effect of pindolol on the L-5HTP-induced increase in plasma prolactin and cortisol in man. Psychopharmacology 114, 635-643.
31. Meltzer, H. Y. and Maes, M. (1995) Effect of pindolol pretreatment on MK212-induced plasma cortisol and prolactin responses in normal men. Biological Psychiatry 38, 310-318.
32. Moghaddan, B. and Bunney, B. S. (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. Journal of Neurochemistry 54, 1755-1760.
33. Moller, H. J., van Praag, H. M., Aufdembrinke, B., Bailey, P., Barnes, T. R., Beck, J., Bentsen, H., Eich, F. X., Farrow, L. and Fleischhacker, W. W. (1994) Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology 115, 221-228.
34. O'Keane, V. (1995) Dynamic serotonin neuroendocrine challenges in depressive disorders: what have we learned? Journal of Serotonin Research 1, 101-111.
35. O'Keane, V. and Dinan, T. G. (1991) Prolactin and cortisol responses to D-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. American Journal of Psychiatry 148, 1009-1015.
36. O'Keane, V., McLoughlin, D. and Dinan, T. (1992) D-fenfluramine induced prolactin and cortisol release in major depression: Response to treatment. Journal of Affective Disorders 26, 143-150.
37. O'Keane, V., O'Hanlon, M., Webb, M. and Dinan, T. G. (1991) D-Fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clinical Endocrinology 34, 289-292.
38. Reyntjens, A., Gelders, Y., Hoppenbrouwers, M.-L. and Vanden Busche, G. (1986) Thymosthenic effects of ritanserin (R55667), a centrally acting serotonin-S2 receptor blocker. Drug Development Research 8, 205-211.
39. Silver, H., Blacker, M., Weller, M. P. and Lerer, B. (1991) Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study. Biological Psychiatry 30, 523-525.
40. Spina, E., De Domenico, P., Ruello, C., Longobardo, N., Gitto, C., Ancione, M., Di Rosa, A. E. and Caputi, A. P. (1994) Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. International Clinical Psychopharmacology 9, 281-285.
41. Van Praag, H. M., Lemus, C. and Kahn, R. (1986) Hormonal probes of central serotonergic activity: do they really exist? Biological Psychiatry 22, 86-98.
42. Wiesel, F. A., Nordstrom, A. L., Farde, L. and Eriksson, B. (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114, 31-38.